150 related articles for article (PubMed ID: 36469914)
1. Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD.
Schechter M; Jongs N; Chertow GM; Mosenzon O; McMurray JJV; Correa-Rotter R; Rossing P; Langkilde AM; Sjöström CD; Toto RD; Wheeler DC; Heerspink HJL
Ann Intern Med; 2023 Jan; 176(1):59-66. PubMed ID: 36469914
[TBL] [Abstract][Full Text] [Related]
2. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
[TBL] [Abstract][Full Text] [Related]
3. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
[TBL] [Abstract][Full Text] [Related]
4. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.
Schechter M; Wiviott SD; Raz I; Goodrich EL; Rozenberg A; Yanuv I; Murphy SA; Zelniker TA; Fredriksson M; Johansson PA; Leiter LA; Bhatt DL; McGuire DK; Wilding JPH; Gause-Nilsson IAM; Cahn A; Langkilde AM; Sabatine MS; Mosenzon O
Lancet Diabetes Endocrinol; 2023 Apr; 11(4):233-241. PubMed ID: 36878239
[TBL] [Abstract][Full Text] [Related]
5. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
[TBL] [Abstract][Full Text] [Related]
6. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin in Patients with Chronic Kidney Disease.
Heerspink HJL; Stefánsson BV; Correa-Rotter R; Chertow GM; Greene T; Hou FF; Mann JFE; McMurray JJV; Lindberg M; Rossing P; Sjöström CD; Toto RD; Langkilde AM; Wheeler DC;
N Engl J Med; 2020 Oct; 383(15):1436-1446. PubMed ID: 32970396
[TBL] [Abstract][Full Text] [Related]
8. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
[TBL] [Abstract][Full Text] [Related]
9. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
[TBL] [Abstract][Full Text] [Related]
10. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
11. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
Chertow GM; Vart P; Jongs N; Toto RD; Gorriz JL; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefánsson BV; Langkilde AM; Wheeler DC; Heerspink HJL;
J Am Soc Nephrol; 2021 Sep; 32(9):2352-2361. PubMed ID: 34272327
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
Wheeler DC; Jongs N; Stefansson BV; Chertow GM; Greene T; Hou FF; Langkilde AM; McMurray JJV; Rossing P; Nowicki M; Wittmann I; Correa-Rotter R; Sjöström CD; Toto RD; Heerspink HJL;
Nephrol Dial Transplant; 2022 Aug; 37(9):1647-1656. PubMed ID: 34850160
[TBL] [Abstract][Full Text] [Related]
13. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
Heerspink HJL; Kiyosue A; Wheeler DC; Lin M; Wijkmark E; Carlson G; Mercier AK; Åstrand M; Ueckert S; Greasley PJ; Ambery P
Lancet; 2023 Nov; 402(10416):2004-2017. PubMed ID: 37931629
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study.
Beernink JM; Persson F; Jongs N; Laverman GD; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Toto RD; Wheeler DC; Heerspink HJL
Diabetes Care; 2023 Mar; 46(3):602-607. PubMed ID: 36662635
[TBL] [Abstract][Full Text] [Related]
15. [The dapagliflozin and prevention of adverse outcomes in chronic kidney disease: results of the DAPA-CKD study].
Batyushin MM
Ter Arkh; 2021 Jun; 93(6):713-723. PubMed ID: 36286839
[TBL] [Abstract][Full Text] [Related]
16. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.
Heerspink HJL; Sjöström CD; Jongs N; Chertow GM; Kosiborod M; Hou FF; McMurray JJV; Rossing P; Correa-Rotter R; Kurlyandskaya R; Stefansson BV; Toto RD; Langkilde AM; Wheeler DC;
Eur Heart J; 2021 Mar; 42(13):1216-1227. PubMed ID: 33792669
[TBL] [Abstract][Full Text] [Related]
17. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
Heerspink HJL; Cherney D; Postmus D; Stefánsson BV; Chertow GM; Dwyer JP; Greene T; Kosiborod M; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Toto RD; Wheeler DC;
Kidney Int; 2022 Jan; 101(1):174-184. PubMed ID: 34560136
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.
Rossing P; Inzucchi SE; Vart P; Jongs N; Docherty KF; Jhund PS; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; DeMets DL; Bengtsson O; Lindberg M; Langkilde AM; Sjöstrand M; Stefansson BV; Karlsson C; Chertow GM; Hou FF; Correa-Rotter R; Toto RD; Wheeler DC; McMurray JJV; Heerspink HJL;
Lancet Diabetes Endocrinol; 2022 Jan; 10(1):24-34. PubMed ID: 34856173
[TBL] [Abstract][Full Text] [Related]
19. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
20. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
Wheeler DC; Toto RD; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Pecoits-Filho R; Correa-Rotter R; Rossing P; Sjöström CD; Umanath K; Langkilde AM; Heerspink HJL;
Kidney Int; 2021 Jul; 100(1):215-224. PubMed ID: 33878338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
